Şeyma Bardakçı

Dr. Şeyma Bardakçı

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ŞBŞeyma Bardakçı
Şeyma Bardakçı
MBMuhammed Raşit Bardakçı
Muhammed Raşit Bardakçı
DEDerya Güzel Erdgan
Derya Güzel Erdgan
AAAbdülkadir Aydın
Abdülkadir Aydın
AYAhmet Bulent Yazici
Ahmet Bulent Yazici
Background/Objectives: Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) can affect both the liver, where clotting factors are synthesized, and the coagulation system, which prevents acute bleeding. Methods: This study included 451 inpatients undergoing addiction detoxification and 150 healthy controls. Patients were stratified by substance type: Alcohol (n = 110), Cannabinoid (n = 71), Methamphetamine (n = 110), Multiple-Substance (Methamphetamine + Cannabinoid, n = 110), and Opioid (n = 50) users. Age-matched control groups (mean ages 45, n = 50; 30, n = 100) were used. Serum levels of Ca, INR, PT, APTT, PLT, AST, and ALT, alongside sociodemographic variables, were assessed. Results: Significant group differences were observed in ALT, AST, PT, APTT, and PLT (p < 0.001). Notably, PT was lower in Multiple Substance and Methamphetamine users; APTT was elevated in Cannabinoid users; AST was higher in Alcohol users; and Methamphetamine and Opioid users exhibited both decreased AST and ALT. Post hoc analyses confirmed substance-specific effects (p < 0.001). Regular cigarette use was significantly more prevalent among alcohol and substance user groups compared to controls; however, smoking did not exert a significant effect on the evaluated biochemical or coagulation parameters. Conclusions: These findings demonstrate that liver enzymes and coagulation parameters can vary significantly by substance type. Observed alterations in AST, ALT, PT, APTT, and PLT suggest that substance use may exert substance-specific effects on hepatic and haemostatic function, highlighting potential risks for bleeding or thrombotic complications. Monitoring these parameters in AUD and SUD patients could provide valuable clinical insights, allowing for more tailored and proactive management strategies. While the underlying mechanisms remain to be fully elucidated, these results emphasize the importance of considering substance-specific physiological impacts when assessing liver and coagulation health in addicted populations.

25 December 2024 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
MBMuhammed Raşit Bardakçı
Muhammed Raşit Bardakçı
AYAhmet Bulent Yazici
Ahmet Bulent Yazici
ŞBŞeyma Bardakçı
Şeyma Bardakçı
EYEsra Yazici
Esra Yazici
There is a need for treatments that can reduce cravings in methamphetamine use disorder (MUD), which is trending upwards worldwide. The aim of this study was to evaluate the effect of modafinil treatment on substance craving in patients with MUD. The study included 100 patients with MUD who were being treated in an inpatient detoxification center. Patients were divided into two groups as modafinil group (MG) (n = 51) and non-modafinil group (NMG) (n = 49) and compared with each other in terms of sociodemographic data, severity of addiction, change in craving scores on the 1st, 7th and 14th days. The change in craving scores during the first week was found to be significantly greater in the modafinil group (MG) compared to the non-modafinil group (NMG) (p < .001), indicating that modafinil effectively reduced methamphetamine cravings within the first week of treatment. When the changes in craving levels were compared between the groups in the first and second week, the difference between the groups was not statistically significant (p > .05). The mean substance craving scores at hospitalization were higher in MG than NMG (p < .001). Modafinil may be beneficial in the treatment of MUD, especially when used in the first weeks of treatment, especially in patients with higher cravings at baseline.